Amlexanox
Metabolic Modulator / Anti-InflammatoryapprovedAlso known as: Aphthasol, IKKε/TBK1 Inhibitor, AA-673
An anti-inflammatory and anti-allergic compound that inhibits IKKε and TBK1 kinases, showing promise for obesity, type 2 diabetes, and metabolic syndrome through unique energy expenditure mechanisms.
Overview
Amlexanox is a small molecule originally approved as a topical treatment for aphthous ulcers (canker sores) that has gained significant interest in the metabolic and longevity communities after research revealed it inhibits IKKε (IκB kinase epsilon) and TBK1 (TANK-binding kinase 1) — two kinases that become elevated in obesity and create a cellular 'energy conservation' state. By inhibiting these kinases, amlexanox reverses the metabolic adaptation that makes weight loss difficult, increasing energy expenditure and improving insulin sensitivity. While not technically a peptide, amlexanox is frequently discussed in peptide community circles alongside compounds like 5-Amino-1MQ and tesofensine as a novel approach to metabolic optimization. Clinical trials have shown improvements in HbA1c and metabolic parameters in type 2 diabetic patients.
Mechanism of Action
Amlexanox targets metabolic inflammation: (1) Inhibits IKKε, a kinase upregulated in obesity that suppresses thermogenesis; (2) Inhibits TBK1, which creates an energy-conservation feedback loop in adipose tissue; (3) Dual inhibition increases energy expenditure and uncoupling protein expression; (4) Improves insulin sensitivity by reducing inflammatory kinase signaling in adipocytes; (5) Restores catecholamine sensitivity in adipose tissue for improved lipolysis; (6) Anti-inflammatory effects through suppression of NF-κB pathway activation; (7) May improve hepatic steatosis through reduced liver inflammation.
Molecular Formula
C16H14N2O4
Molecular Weight
298.29 g/mol
Sequence
Not applicable — small molecule, not a peptide
Dosage Protocols
Dose Range
50mg – 100mg
Frequency
Three times daily
Route
oral
Cycle Length
12 weeks (based on clinical trials)
Based on clinical trial dosing for metabolic endpoints. Take with meals. Not commonly prescribed off-label yet. Medical supervision recommended.
Source: Oral et al., 2017 clinical trial
🧮 Personalized Dosage Calculator
💰 Estimated Pricing
Typical Supply
5mg tablets or paste
Last Updated
2026-02
Previously FDA-approved for aphthous ulcers (Aphthasol). Discontinued brand; compounding pharmacies may still prepare it.
⚠️ Prices are estimates based on publicly available data and may vary significantly by vendor, location, and prescription status. This is not medical or financial advice.
Side Effects
| Effect | Severity |
|---|---|
| Diarrhea | mild |
| Nausea | mild |
| Rash | mild |
Pros & Cons
Targets a unique metabolic pathway — reverses obesity-induced energy conservation
Already FDA-approved (for a different indication), so safety profile is established
Oral administration — no injections required
Improves insulin sensitivity independently of weight loss
Clinical trial results for metabolic endpoints were modest
Not FDA-approved for metabolic indications — off-label use only
Three-times-daily dosing is inconvenient
Not a peptide — included for community context only
Research Studies
🩸 Blood Work
No specific bloodwork requirements reported for this peptide. General health panels are always recommended before starting any peptide protocol.
Legal Status
FDA-approved as Aphthasol (topical paste for canker sores). Off-label oral use for metabolic conditions is experimental. Available by prescription. Being studied for metabolic indications.
Readers Also Viewed
Semaglutide
99An FDA-approved GLP-1 receptor agonist used for type 2 diabetes and chronic weight management, producing significant weight loss of 15-17% body weight in clinical trials.
BPC-157
98A 15-amino acid synthetic peptide derived from human gastric juice that promotes healing of tendons, ligaments, muscles, gut lining, and other tissues through multiple regenerative pathways.
Tirzepatide
97A first-in-class dual GIP/GLP-1 receptor agonist that produces up to 22.5% body weight loss, approved for type 2 diabetes and obesity management.
CJC-1295 + Ipamorelin (Combo)
95The most popular growth hormone peptide combination, pairing a GHRH analog (CJC-1295) with a ghrelin mimetic (Ipamorelin) for synergistic GH release with minimal side effects.
Related Peptides
Semaglutide
An FDA-approved GLP-1 receptor agonist used for type 2 diabetes and chronic weight management, producing significant weight loss of 15-17% body weight in clinical trials.
BPC-157
A 15-amino acid synthetic peptide derived from human gastric juice that promotes healing of tendons, ligaments, muscles, gut lining, and other tissues through multiple regenerative pathways.
Tirzepatide
A first-in-class dual GIP/GLP-1 receptor agonist that produces up to 22.5% body weight loss, approved for type 2 diabetes and obesity management.
CJC-1295 + Ipamorelin (Combo)
The most popular growth hormone peptide combination, pairing a GHRH analog (CJC-1295) with a ghrelin mimetic (Ipamorelin) for synergistic GH release with minimal side effects.